Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Danish drugmaker Novo Nordisk has released fresh clinical data on two of its lead investigational assets, seeking to bolster ...

By Sanchayaita Roy and Sukriti Gupta (Reuters) -European shares were mixed in choppy trading on Monday, amid escalating ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...

Patients who took a lower dose lost more weight on average. Read more at straitstimes.com. Read more at straitstimes.com.

The Financial Times, reported but not verified by Reuters, covers British Airways and Singapore Airlines canceling flights to ...

In addition, the company reported a 21% mean weight loss in a higher dose cohort of the 7.2 mg formulation of Wegovy ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

Once-weekly medication results in weight loss of up to 22.7% in adults without diabetes and 15.7% in those with type 2 diabetes CHICAGO, Ju ...